-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 B41+s/+HxGBsOh6yM6MgSP5w6STtItjZwcRBX25VzJ71oITkC5w8OGlx/WhMB7Qc
 7aa1g6TdPvyhp0nsZgwr4Q==

<SEC-DOCUMENT>0000950144-04-012377.txt : 20041223
<SEC-HEADER>0000950144-04-012377.hdr.sgml : 20041223
<ACCEPTANCE-DATETIME>20041223154445
ACCESSION NUMBER:		0000950144-04-012377
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041223
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041223
DATE AS OF CHANGE:		20041223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AAIPHARMA INC
		CENTRAL INDEX KEY:			0001013243
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		IRS NUMBER:				042687849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21185
		FILM NUMBER:		041224259

	BUSINESS ADDRESS:	
		STREET 1:		2320 SCIENTIFIC PARK DRIVE
		CITY:			WILMINGTON
		STATE:			NC
		ZIP:			28405
		BUSINESS PHONE:		9102547000

	MAIL ADDRESS:	
		STREET 1:		2320 SCIENTIFIC PARK DRIVE
		CITY:			WILMINGTON
		STATE:			NC
		ZIP:			28405

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIED ANALYTICAL INDUSTRIES INC
		DATE OF NAME CHANGE:	19960430
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g92256k3e8vk.htm
<DESCRIPTION>AAIPHARMA INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>aaiPharma Inc.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">





<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 10pt">CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(D) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934



<P align="center" style="font-size: 10pt">Date of Report (Date of earliest event reported) December&nbsp;23, 2004


<P align="center" style="font-size: 24pt"><B>aaiPharma Inc.<BR>
<HR align="center" size="1" noshade width="85%"></B>


<DIV align="center" style="font-size: 10pt">(Exact Name of Registrant as Specified in its Charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">0-21185
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">04-2687849</TD>
</TR>

<TR style="font-size: 1px">
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other<BR>
Jurisdiction of Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">2320 Scientific Park Drive<BR>
Wilmington, North Carolina 28405<BR>
<HR align="center" size="1" noshade width="85%">


<DIV align="center" style="font-size: 10pt">(Address of Principal Executive Offices)</DIV>


<DIV align="center" style="font-size: 10pt">(Zip Code)</DIV>



<P align="center" style="font-size: 10pt">(910)&nbsp;254-7000<BR>
<HR align="center" size="1" noshade width="85%">


<DIV align="center" style="font-size: 10pt">(Registrant&#146;s Telephone Number, Including Area Code)</DIV>



<P align="center" style="font-size: 10pt">Not Applicable<BR>
<HR align="center" size="1" noshade width="85%">


<DIV align="center" style="font-size: 10pt">(Former name or former address, if changed from last report)</DIV>


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below):



<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><FONT face="Wingdings">&#111;</FONT>&nbsp;</TD>
    <TD>Written communication pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>
</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><FONT face="Wingdings">&#111;</FONT>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR
240.14a-12)</TD>
</TR>
</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><FONT face="Wingdings">&#111;</FONT>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))</TD>
</TR>
</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><FONT face="Wingdings">&#111;</FONT>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17
CFR 240.13e-4c))</TD>
</TR>
</TABLE>


<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">






<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">









<P align="left" style="font-size: 10pt"><B>Item&nbsp;7.01. </B><U><B>Regulation&nbsp;FD Disclosure</B></U><B>.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;23, 2004, aaiPharma Inc. (the &#147;registrant&#148;) issued a press release announcing that
SICOR Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., has
reacquired its U.S. marketing rights for calcitriol injection in exchange for certain payments to
the registrant. A copy of the press release is furnished as Exhibit&nbsp;99.1 and is incorporated
herein by reference.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01. </B><U><B>Financial Statements and Exhibits</B></U><B>.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Exhibits

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="75%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of aaiPharma Inc. dated December&nbsp;23, 2004
announcing the reacquisition by SICOR Pharmaceuticals, Inc. of its U.S.
marketing rights for calcitriol injection</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">***


<P align="left" style="font-size: 10pt">Note: The information contained in Exhibit&nbsp;99.1 shall not be deemed to be &#147;filed&#148; for the purposes
of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section.



<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


<P align="left" style="font-size: 10pt">Date: December&nbsp;23, 2004



<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">aaiPharma Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/&nbsp;Matthew E. Czajkowski</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Matthew E. Czajkowski, Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><U><B>Exhibit&nbsp;Index</B></U>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="75%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="17%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="78%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of aaiPharma Inc. dated December&nbsp;23, 2004
announcing the reacquisition by SICOR Pharmaceuticals, Inc.
of its U.S. marketing rights for calcitriol injection</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">4
</DIV>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g92256k3exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Ex-99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="right" style="font-size: 10pt">Exhibit&nbsp;99.1



<P align="center" style="font-size: 10pt"><IMG src="g92256k3g9225600.gif" alt="(Letterhead)">


<P align="center" style="font-size: 12pt"><B>aaiPharma Announces that Sicor has Reacquired Marketing Rights to Calcitriol</B>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Wilmington, N.C., December&nbsp;23, 2004 </B>&#151; <I>aaiPharma </I>Inc. (NASDAQ: AAII) today announced that SICOR
Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:
TEVA), has reacquired its U.S. marketing rights for calcitriol injection&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in exchange for
certain payments to <I>aaiPharma</I>. Additional details were not disclosed.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Calcitriol injection vial is a drug used primarily to treat chronic kidney dialysis patients
with abnormally low levels of calcium in their blood.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>According to Dr.&nbsp;Ludo J. Reynders, President and CEO of <I>aaiPharma</I>, &#147;This transaction represents a
small but important step in our initiative to rationalize and simplify our business.&#148;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>About </B><B><I>aaiPharma</I></B></U></TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>aaiPharma </I>Inc. is a science-based pharmaceutical company focused on pain management, with
corporate headquarters in Wilmington, North Carolina. With more than 25&nbsp;years of drug development
expertise, the Company is focused on developing and marketing branded medicines in its targeted
therapeutic areas. <I>aaiPharma</I>&#145;s development efforts are focused on developing improved medicines
from established molecules through its research and development capabilities. For more information
on the Company, including its product development organization AAI Development Services, please
visit <I>aaiPharma</I>&#145;s website at www.aaipharma.com.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">###




<P align="center" style="font-size: 10pt">5
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g92256k3g9225600.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g92256k3g9225600.gif
M1TE&.#EA^P+``/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI26EI:6F-C8V-K8VMK:W-S<W-[<WM[>X2$A(2,A(R,C)24E)2<E)R<G*6E
MI:VMK:VUK;6UM;V]O;W&O<;&QL;.QL[.SM;6UM[6WM[>WM[GWN?GY^?OY^_O
M[^_W[_?W]___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````^P+````(_@!7"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX`#"QY,N+#A
MPX@3*U[,N+'CQY`C2YY,N;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7K
MU[!CRYY-N[;MV[ASZ][-N[?OW\"#"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KU
MZ]BS:]_.O;OW[^##_HL?3[Z\^?/HTZM?S[Z]^_=;/TB83[^^?1$3-=C?7Q^^
M?_,<`"#@@`06J(`*$DE0X(($_N>@>`$R*&$&"4K(X(,G(:CA0`ABV-H&%DJ(
M'T01A%B@ARAJ%Z&)!"[0H4,*LBA@BB-IJ,*+`N%((VDKRB@@!A#%*...*.E(
M)(\^%AC"0T*R>&1(1JX0Y9.=@9CD@`=,:5")/E()DHY:>JE9CU=6`&.2#NIH
MP@<=F)#CC06%&:>4=*+P``,0//#``@R,&->+<HKI$9E7@M!0DR:FR$$!`A;P
M`411&DF"``%4*J``;K8%)IV!"KH1H4EFR1"B(?JWH4`8'`!```(F@,*&_K`>
M=..F.:[``:L$&M`I6'#2.="KGIZDP94+FKD0!&AB&,(`JS8;`)`=BD""M-.2
M8*VTU**``J>^(B@DK@V\I>6NP5X$ZI4<+$2JA:9R.(&EN`)@08<D,&MBI04\
M$,*VIZJ@:H$8D,LK02:@8(+`Y59T;JC;)K2NA!X^(*"EJVHP$`GQQDM@O`(,
M,`&_OQ+0[*6/BHL@"A]4(`$$&2"<L$0+)RF!0@]?*!$)'W"`P7X8<,#!""XO
MI<((/EO`GP0^?^#GP"HHJ'$#P*K0@;,#&E"`U1D/J(";T5+<:,-LO8@"!A9T
MT$'.%7#MZ\L;64GL@NDBA&R7#DE=P94-9$""_L,R6M#0U"P:RE#,`X9KD`@9
M*/#V`QP$_10'S.**0,,(8L`JQ07LC:JJEZ\:0`4O=J`Q`(:[U6$($ZP`@0D2
M=)!!P&Q_1+B/!X!=4,T+-F1"JF]K77)!'\BH0$-WLPCDJ#+&/5`(BO>.I?)=
MW9C`@([6JL($`^):0(>5>RV@`9FND$&Q:[NEP0<JS%O!!R$\X'CL"LWNXP,(
MX7[B0AS\Z[S62Z^`@OXALIVL:-<0'X$-!?:[T@,TYQ45D*`#(<C4BQ@PLDHU
M`%8J0$#G+I<N!+UK8TN2"P<>)0$,-$!:[H-?1^3G(^@-)($#4@@*'+`_";G0
M`C+JP$(`)Z,0)D0$_C(RU@I(`,`:8HF!6-&1`#N$@)$)R&]2.IG$L@;%%3!`
M8P,`5ESD8P*_]<P"57R?"@GB-B,*J`0&F=N0$%*"(IKQB00!(HN$B)#BR>AX
M"9%?"$W@QC<>('Q;@9,6"5(`C07@=SE"EB'QJ$$"%:!\:^D0"B:0,Q6(@`,G
M)(@8QVBK-P[(`0:!X8P.PD=/,@B/*VA>B`Z@$!5<B94T8Q$L5R#*WLUL)>.2
M%21KQ<NU`:J7O?+?Q497`+5U2&(;`P#ZI,0H`B4`F-RRGB\YQ+U=SDF:TOPE
M-&,%J&!N$Y*GXA:],)`!#F@``PS<)"<[:4H`;.!VR2K(_]K)(.6-CT5(_BP(
M#WTD.(3T32#!HV>!$)D207+(?[VJYC>Q><TH"7"?JQJ>013GM0+P"P4"F)B`
M#%=-;<*IFP:QW4</"C8M`5*7FKPFIQ)JD()%L7Q3>I4ZUUD0%EX)B;4\"`T%
MNJ`1H2!Y";&CCU!9D!'(*%/(-%$%0H`?$HP@`WUDD*A*$LY:B:`""CC`U1`P
M@0[82)R^(@$&&*#5`B@``AP`F4'89P(33,MB&Q(JJU)GD"9NC`%T$EV!S+0M
M%&B``5=;0`?X-:N42DD#$TA``0IP@`=88$0??9'2VFJ"$'BUK_(AP`.VI31M
M64L#DNP`!*S&59!]M`,,,(`!$-"`N%6UFB'`_NH!"+#:"HB@K[`2($TK4D9/
M;G8@7%HC06QZ@`R(X&0=J"7]!))4"]&Q(&^;I4&&92*)F@"H(6UNB'18)`U]
M``(%R"C%+D>`"JB54\DU@-<N%X`#0&!O."(!`0(P@([1-YVJG!AW.66"R$TL
M`%X5R-TT1J'V9;2"!K"8051@@@HT8+[9:]8`%#!87W:`4AT3@``(@"`+J'=5
M,S,!HS0\@$JUU0(:W&`!(,`O$TP@Q<X2``)T:"04<.`!!#@PU01@@.?N]E.A
M2I*":1G/'$5U00[0[0H^<.2!"@2B4D5("'KGPX)HMYX"F;*)I!NG_#)(`27,
MT.FF%V&-7@H`JRN(_@D:4*#162H!.KJ5QG1U,9&-3``B70'VO&8`@I"90-]=
M$*LR2H`E5;,#A6PS@R@43.P!0,<,4,$#.$8"%02H<P!`P`>:B2NOM6P%G#/S
M@`@`V6A]6-2>\QP$M/EC<R4I?TD:44Z'ZZ,+)D3++)*H*UF$1H-@H'=$S9&,
M&C8[B2)D:@V00`7,R=23G@1L"8A7`1!P`'ME3`!5E!*;*Q4``AS``.+%548'
M0&,Z.?J_I5O!A<V\O8,RV8D`6.X*3&``JFD6U1&^Y4`R8.=''P`!$.98I@VR
M[?]68&KL%54%LI8`"C(H`!D-EP(P3#6-#GD@`#3`M\5;00!;L]43L2G1_I)T
M("+3#>,&7(A00Z2Y7YO(A0)ILH6XG&46Z5M^_=N)AD1F``N0H&$DN'(`+'I1
M2G$U!'`*@05TW"P%4$X%?QY0&,\],01P2P3UQO0`2J:"#QAR50)(@)ZBW>8!
M(#V*;!Z`!#)P,/]EP*[9$X"AH\CI2VF@B#-3@9<?+8`#-.`!$U\08P&0KP<T
MP%X%RKN4VEIB!*"37R1@<YD1,%*06X2Z,L)/+2D47"<-!`1#98@<642A%8!>
MJ6O=7S_WS:+]]M9"&,BY3E10`"CBR%_)Q-0P)9#G%4C>D8""L$:KG%]6A:MA
M(FBDLPAP<1Q2+0`&V%>.*#@ZY4&=W"45B`D"_MZL*IL@:P5H0,8\KH)^:U0"
MW+/<!ENE.0;;.5[+M1'S"=LA$8O:HI;/B$WQ,T\?B6#6J.(C5980,B<@\B9S
M-.=RP&805U8@4[4"H^<C)<0!'3`"2B834H-!&N)\=T98*&`!E$--&C`ZDT,G
M(L!T```^=+)]"_(`;((!BE5Q".!#-^)EK`):OC(^F`8`C4,G&A!@UH,@#D<@
M2Q-0&T-H"9!5!.`F(C`ZF18U_F-^`K(UA25I"Q(NL$)CW*1&U*-0^1=RL280
MQ/5[GB<09!@BG2)*K&<B^52`,R=/QD,0/V5$#S`!'"![+!%.OS2"_Y5I7GA0
M.<)#!R9OZM9IJY)N_B109H\V7H[$>VN#41L4`'"&(WJE,8]259!$AA!G._=T
M9AD%`00#4!%V7RGU8>*63RO`@<VB;Q\W$!^D4>DV4[LE<B_$4P1!0`W!0B,@
M$(GX<@2!:\Y39<`H(0.H@&^$-!=H$BS535:(:>FV4N&DBD_T(ADP.K:G;F66
M-1J5`#1()QBS((SV4EYWA)4&B-.T`G#7**<R8`;"-<%4C0.247A5>:<F(`0`
M3#BD,<^UC+Z2C@)"5U]H$:]G(7[2?^TT$!'(4Q:R7V>X(!%`$)TH(1Y@(J@4
MD5\64CR%`<Y&5;JD(1U08A$6;+(B`J$V,56V9]E391;)*AJ'`$G8`!9P_H>_
MY%T59P!0*(8:Q2J49XXI)5:4XBQ61Q#BYSFLP@"H*!`H>3G[Q2'"5RE6]TN*
M1"`79UB<D@$'%B]<%Y`4L7^_*%`(J9`LHCRS0Q![1R##LP"K1!`-*)4'85/$
M`G,D$4R%-6\64)8"P'^_(DP"@0)0)6@#@"-#>"DX0BH<5C>H8HW9)S[D,RXD
M(`$<1R`II"%-U#D$<%X$X7#B]E+>J&.L0HA,!&^7Z$LV0@(5,#W$-$A:"3-A
M2!`40$]?"98AHCQS&"(CTHL60B$6N2""LVLALI$K8(SM-"_*R)-\^0")IHW%
MQ),KH`$-<&JC0V<#$76$AR-3Y"PTEQ`=LG(!_C!D+V(!HU-Z!R$"*`:23LB*
M*U!ON:(07O9(Y1,"AF2>_E-(ANA2!T$"S-E,HB:)WI2:$$&+FN2&\920L+E7
M!+%R<",0F"<A;G)=(7(\P]B""@&<IB227U(G'``!"/"3,@8!CNE$D2DE*",!
MU59U+(-XK5(04OA,!)&.<]4I+Z*)NJ>9*L"%CP9?)I@!#)!C`C(`"8"CWUDK
M*&"B`(!7UI1H`Q*4:U,\\7)Q"%*)S8)_470CF)2A.XH`$``!63,!LFAY`RDB
M!O&@-?2:`\H@#[D\)G)+9:DU`Y&F`@)+$EH@<#E<`/J6'(D@&J!\E:(`RY2;
MI8<@(M!,E!(`#!!@_M_G1*LV$";`<:P"BAR"GQ-#4`UAFE5#E0J0,?=8*XX&
M<0!``&QGAA6'2%.6,:GC4"#9+"FD2=3G+)!JH'C%+QF@6D1).B$D5P"PE/P9
M$5SI:Z8DIF.:>`4A<T-D(N"9FTJ22B82*);&IL[S@"+1I)Q6*>\E3"C9+.B#
M(/16(+8FBC_YC]PSC@0RJMI7JA-SE`OAJ`,WDW#'D@0Q`2:ZG2>C`O6X*L=%
M)Q+*:$82JM_:4NB9/>6X(8')K0@".04B`+"S+7/3:4BTI325J_*DK%?"J[TZ
M(.8IC3U%K`32:\':H`SJ7!#A5UCE27'*$0@2`NHU:&BFF4,Y('\IAJ:X_BH)
MT'9(N8/<Z7R=<W%Z!7P/8:U">JIR^'X"0J0HH`#^U6TXB"`?8&VL4ID<\GNX
M8JL$X9U.!)X#,8[2MD3XJ912\@'<QRJ@\U*JQ"KM=JM@Z".[&)Z>Q"$^H@`B
M,`(BT+9LZ[9MN[9Q^[9R"[=M>U(;:T/*:FP"@98S9X3$2!$H$`(<(`$.&R*@
M1!(&.2"0%7,1UF?N9V8#`+-2(IW*M**@Z2M4URJ[XI$+`I"_.#I:JI@``R@+
M=V9#NE)""@!J(TZ2.B"AZ8I7&*6\>)H,MKH!$#YNLJ\"@J1B&Q$):B)X2+I&
M1!``2A)[:R+91KP2HJS7.1$H(`(;@`&'>S\C_O$!*!BV.;*OK**BV.M$1%I_
M=5<IZ52/Y"N4"Q)I$6$Y`-.6\`9%40EV<X<@*8LKK'B"!;*$NP2O\)9SS357
MO>2>$09GXK.#`V<]X@H`?/N[#\&P"U:]B3(0!BHAY`ID^S.`>?LV%'H1-@:@
MP[L1_XIF.`*X!BA@SV>O`D&QVKMNCG1`Y@H`\(F=`C&$37L0_\N#`L&[A'=0
M++@Q"G8C$OI,>KADBKJI`H0".AP`UG=8G^L__L@JU\B\`L*H#-R?JXD0`OHV
M!`%E$S(2LQE=!P'!#(*Q$I&,1I9Y-<(H&0,M>UFI&0-%XJ<Q\PJB61<OPY.=
MS7)@=UQS._AI#X$"_CZ[*LZ&>WW(?R+3.2HJ3#U2*9/KKUF:$!3[3+;S?9;J
M;)G:+#J$`MR&:?O%8/\2+U);Q;F8)&6;1\6+MC+"K`AQA[<U$1-\1P=AL;FV
M$)9$-#XS'\BTP.[+(KZY$1C59JAT*Z-8>O]Z2+YBA/$RNC-<9J#[IAWT$"&`
M@OI;$/4RL`=3J-GSE!VBB0`P53?B1N$H30T)BCB"KT>J3=IUEQG;9CV8PE@F
MR@_1I0SRP<P5I@3QI@RRO`9!L2NS;!38ME/"Q3U4G\X3IZ+DM#4E7"$1I,]'
MP.IVM;"[S%2#?KS82!FS7T@\BIW,M`-2P;+2B9(3R^LG*@S]7],\-JM+_C\:
MHLD#2Z[\FS'//!"7ECU4[&?YJWV&.#&GJ@&'7"#T#,^TYG\,89N]HV9)<@&1
M@L_O?!!SBB4)X;?$<H%KN2`'X-%0;2&$^"66*Z@FU'?FJL0"X314@P"EV6T)
M+`"?A@)$W2@25'[@9\8//#I=>RKU6\(WHL.;.@$3P"@O/(]9NR`.[4L93%^#
MA"`#AI4@Y:CZZ3^AMD$P>46P>F?HDYA`;1`.G!#R7(8#0;$6H@`>`#8F`&NU
M%J%OH\\#D=D2$L,XF;:RAP*O#*<EL70Y+6X=\"Y,IP#F%2&&-&@5,)F/UKO"
M"8RL4G+:]YB]V[E2TMBK$LH"0783@VT=<D68_D8Q!\"'!"(`#T!C")<]SVA5
M\,*28!*_$'=<W73(N!*^8CVPC4("5]2'#`!:"OMC_LD0.Z7%<=+4-=3+$/@V
M`RB';X/09RPS=\BV''`!;JC*(#$VVPJ4.D0"69<]W#BC$!U1+=,!DBHY;J*#
MV9-W-T+"4]Q+K83-N$)JO_3+.3EWFS;;Y85T#8""`C"ZI\N68*4"PZ(QY'Q0
MTEF8[I8U%*T"")3`EZ)I$"A\$^,JE;T0P4N;#E%*]ET08"I0'L`08MS-"S'5
M4A4F2<Y3(?L1'Z!8E],`'P`V(9"A0S>H5G5XJS(`,_8B:P9Q`X!6'?(!$Y`!
M'6!.MF55$V`!&N`S_CL#J=C)8!6@Y^9D`2+).C%9YQ4`KAV2/QAF``N4@P=0
M*0>`3B#:`170,ZXS`:VK27).YQJ`6/T]-ACP@QQ`Z-TB)5>5`2^X/MS"`0F@
M8:PR`/KB*V.>4>'GYT>>T$+M$&X90[L,EAL<U*$7/U<2[`)1WPJ9N"6A+5)B
M61WP<]24M6T"5FIM66HE26Q2:1UUZBN5??JM2]>^Z3:B@0=U(X0;FFIE`C\8
M@JWX6BIUCL+$34&H4()D+2'P`=`.HE*",Q'4+ZT(SY>M+DVNJPII[(AZ)?T-
MATFR>@BQN/1$W"X1*2@%5KSTAQ/?2@W!:B!.RS*L\>6>\1_/$#/)\;2R_F`E
MG^OX0\H=B]_$+E!;'DI)$BA6;I9+CM\^X@#QW9'FR&H\O_,^#TU`#^\]'_1#
M+_0_;_1$?_1%O_1*W_1);_$H3T97S.O$LA`B,.75]=/`XR,^=A!9OF@Y2Z-F
MY,=4DO/R/?5G4F0(86DV7R""-1&\:2*XKO`L`M<&T0%7O3\5X-$;4?+R_O<S
M'OB`/_B"7_B$?_B&G_B(O_B*W_B,'RN:&?6FO.N0,J<.@0(>\-J=;0$)_Q"<
MO2!V7\\FTMT.H718;X`9$/H?45GLT_HB$`*P__JQ#_M,1?NR7_NSG_NXO_NW
MW_NV__NZ[_O!#_R\3_S"7_S#G_S(O_S'W_S&_O_\RN_\NA_[["/Y3F$"B%X?
M,$P?Y21]6A&]')`!])%?#S`?Y33'>?A7#*``?++^"L#^[Z\`[@__[S__"Q#_
M]H__\7__];__^@\0"A0L$*B`04&"`@\*3&@08<&%`R$^5$C1(<.)&"MJO"AQ
MH\>.#2.*M#@R(TB3'TDR/'@0@HH5,67.I%G3YDV<.77NY-G3YT^@084.)5K4
MZ%&D294N9=K4Z=.@,&%"I5K5ZM6K4[%NY=K5ZU>P8<6.)5M6Z%2M*[1*5<LV
M9EJ9:%7,E0I7[5VX;M_JO<D7[]^Y;^,.3AL8Q>"9:Q$'%MSX;^+$,`\7OONX
M,LW`C"-#)FS6\V?0_J%%CR9=VC3GRX+1JD;<NJ9=GGYWPNYK63%;V3H5YY0;
MVS=JX*XQGR9>W/AQY,F50[T=UZY>Z(#;XA[.VGK;O7T9KV9-G;OSQ;M;4W=\
MN/;OYG6#2T41_;9FVLOESZ=?W_Y]L7Z?0XXO'C9L\U*[*\#75IB,,L=0>^X_
MR[3C;S&;-$LPIO8B-/"M`/NK#C\.._3P0Q`]9(N$#TH,(3`3/NB@@P],"(&$
MMF`D44435`C!A+]"T$"##R8+@441:G3Q,!)$&/!$F$SH(`,.8!S,!`XT:'*%
M(6,J4JT2/P@A)B-1-.&P(.?2D0,JLRQQ!1&T/'&%(NE"4BT40FC/!"-E_OK`
M1A9-G$M)*4F@#@411FPOSA6WG/&#(.^2\RT1I.1`!3K#!!0O.54H<<4*0]1T
M4TX[]72KJ4QH8(`&%A"`@2TE`(```AK``(`$YD(AU@D$*.``##X(`(*W2("@
M``PJ&``"%$P@(``%`"@`!08"T$"%!&*%"8-E5]"@U0P8**#.F#XP0($,$FA@
MA0<`\%,%!1"PT58#Q@VAVI@>6$"M`B18(0,#)DC`!`T*$$#96`\XX`$!*D!!
M`0$P6&$"`IQ<08*$5X"`@,E(&(`$!?RU]:4,!$#`@@(`(#,N#`2H,28%*K`6
M@`':56&!`!I(```##!5``S03&$""!P;@@`,`_@*88.%J52"!`!$R8/E6'#]U
MNBL3))!Z:JJKMOIJJ2_XF8-$B</ZZJ?#?JHN`AB8:P(`&%@!`0`^P)+F:8<^
M((&[+`A`X;D."&!D53$0@643!`A`A`,`D),``#J`20)U+0!@7`,S"-786*GL
M8(6,)2-``14Z$*`]F#00H,L,`GA@KIO7OMQ/`__%$84"AD;`@!4JB-D$GRN;
M^?*93U>!`P).-H!7M088&LT!%+@P)@A$-E`$9U6P_=F8$%!>!56'#L'<%1H0
M^;`;(0@``)P9`(!XSTU`&V<)Q7:_J;\!D']^^NNW_W[\&\C`8='PO_]]`!YE
M*I[C5>=HACORW0EZ_@$@`0<08`(2"$`!(9!3LA2W`@S$+#!*>T`'D.5!`T0P
M`/PJ@`$"8($5Y$M7#>/.X@QWF0,@X&>V&]H$!A""'ID``0*P5P@,`("AI0\%
M!$@`!LP3@@`40%8!H&`!,K""#ZP*`A=LB^!(0();[0H%$$``A08@.14(;#)K
M4]>`V&:V#^CM<@VXV9U44(`*P.0#IUH8`7XW`.J]A6UM,Q;;'H`"QH7Q;B\2
M4``-.93X^4^1B\3?!$?#R/D=4I)1J0``,M`>I4TP:`A`U0H&(``.&,!MKRJA
M`@+'0)0)8$T+`X`%2'D`":0H`%V$0`(Z(#\.W!!MQ&-3TV!B``,<2`4H_A!`
M`A30@)`]$0$#F%L'+*``G:G@`4JS@`H8=IAR`>`!:@':Z3"H+`(\<2X_M%=E
M_F;'?HG@7Q@XP/$\!Z/M;3,F)BA`%^_R`8BUS0"Y-!(""#`W%)"`B6JQF[T0
M0+<$$"`Q)@A`0U%PK1`@#@/Y8F@`#K#/0DY2HSI))"0]RDB#A>:C&R6IA6!B
MOD<]S)(<T*!4O/>``C8/9\5BF7FB>1<&W&P"=ZL3T,9U`%ZQ#0'+0IODV(0K
MPQB`;HQ!8HU>ECAU;A,F";``P28P`0VT$G-=A!0#!E#&5ZE,!;]"G-L,Q+;+
MX>66=),`[79Z@`*02049&`!,;JDR;FIS)A+(_F7R,+`]&`U/)IY#P6&:EP%C
MJ>VBJOE;":6GQ+?&]6_!S$U)+2N3$7Q4LXSTYF=&>MG+RFH`@T-!!V*'`KL9
M+#!V.\`P5Z"W'G4N``D`70,"<*<5F%9E###`ZUBI`7H^2U0!F)?C?(=$ULUE
MJ#B"E`HL4-=A(JZ!0"SLN_BE+%\%`+&MLE1[2A4O5<;D6QHP'9P(,+K,?%-E
ML)R+[2@&DW3!!'HO48$("%``L[*I`"2HI-HT4-<(D@F;!H!)QTS)4GLUH&%J
MJ5%6'W`Z!-"W`K:Z;@-<"UH,TZ2CF^5P_?[H68]F^+(DD!\##A!.M33/``7`
M&12U2Z1_%2"N&4RB_@3J6X!=Z4R<!U#>6]A(@HC.Q``8&*9M$S"!BZ9%5PB8
M0`-4EBXNK4IB`1A`JS"P3?L:*5E2`H#!"B`NI$V5=BO8WDL2"B8`"(`PS0M2
MVV22`+45#W+6XN$$"@`!_C6`=B(80*`89L`53P`%RV1``@XP,O$9U9\0>(`"
M^&M)X`X@O\9<@=VJ;`$"B?BR&^YPI[L,8DAJNJ0DZ(`&F!0H`X4@2ON#"8F:
MA@(.9"`#';BBJ34@`C!A``)^>TL'4#V7$IG`12>SD9,L-0$)\#HQ(JC`!(R(
M@C,9B`-W^L"._OJ!<\&H<\`EP:T[-X$,_+I$>[HUF:D'ZU7*Y$=?NM%4_M(T
M*`YLZ2X<@``$4AH7"@XS4);B0$!CG8$3E1H#39)*TII&`@M`H`(X,OB76C05
M$J')UND6M64Y[>D.<XLLGZVX1AE4H+Q8:#89_;B`R',>#4TH/L+IS,@_GE[=
MG'Q"G%FY>#JNT<QB7.?E+`O';R[)Z&C'YB9W3LBOTQP'B7P\2^<-7?SSFI)O
MI^4FI<N#]F+T!`7],D/_^2$OKO/-\D\L/N\Z:%?.\JYPG>G"01!0VI>4W'@G
MHRK_S8;*;LBO@_VC+=YXB.\.0+D_73W2T?K1";]T]Q#=\+4Y>=61CO;-;!WQ
MV.E,U`&SFL0W_C%G_[NG\GX_OXE`]*,7O:JS_JE9GH^%[)U_G]J7POFU@X<W
MNK$[Y*5#(;?/W2<+LCU..`][UG,JYQX=64X(MUFSK#[XRV=^\YUOE,_;K_@Y
MV9YFD^_WYV=?^]OG?I0_.OV<G!Z2&N<)B3B``:MIC6O`EXGR=V)^]%=MX!P8
M`?MY(@)5<^!KZ@\!JHU2WY^)/ZOY&41A"OBSFOFKO^Y;0`;DE.BK'_##":7Y
M*/+KBPZHI(_2'['#"?>+D`O4+`TD"A+(`._I,`6P@`K<B:1)ELUZ@#PZBP_,
MP/UI0!JLP?H8/DB*P)L`FH_*M)I``7;R-`7(+P[$OIPP@2#LM"$$B@]@0;!S
M))X(`2?LM$,+"B0L_APE)$(;W$(N)(T'I!\=M(D)-$*;T``LU#D%2,'V(T.;
MX(`SQ+@TY(FHT;OZH8"5`R0ZU*8-Q`DWU+LX[$)`#,2R^,+Y"<.:F,)%ZC&;
M0`'QTSM#[$`#<8`\Q"6=(($WG$0'H`U+G$0`.(`]I`D4D,1)-$1!+$53=`I"
MI,2=X$&/0B&;,(%+I$-7K(D.+(%8U+M9K(E-Y$3ZB8!7O$6P.X"FN0E;Y$6M
M.D5D3$:FP$%&(L688$6/TL)Y`D:]NP";<#]8-$;Y49C70$1CC$!5T<;4HXEL
MU$9N5$9T3,>@2$7GL8DT>:;-.@`?1`%JI,,-H$4V-)!Z=,2:@$9M[$0"_O&`
M?Y0?#UC$?00[9U1'A51(=N1%'6Q$;20_Y1/%@00`C0NCBIP?(BS!1:J`_F.3
MI#E(^6FMFN#(@51#HN@`J>FWQ-`_>YL)6(N`"D@KF8"U9/O$R(D`OIH4XY,`
ME+3""N"[R)&`"5"UA>L)$=B`K9&2#O#!GH"UG]$)?EG*GQE&J0S*A92DAIQ$
MSJF)K/*H`P@WR5#)CY*G-0PUFO!'10I+5"NM<(0DL\PMS0K*1`$4#O!&_,$K
M*H&D>_Q!B,0?FGS&CV++L7Q+SEJ*5YD?LS2!"KA+^6DQ::*?)WJ+!U`9-TQ!
M2R0R*"H<G5"5<0R*XN/!FAR8O\'"A%0W^7D`_A'@0:'\"='4C?G!OTKZPYQX
MS:P,(&;,2/JQRK<026URRC2*QID@.XR$)`<`3M_,+PQD)&'LB[^\GZFHOK7T
MO058I`5(ML3PS>.TB>"$)&E$)`4X/XWDDMZ4GV>TM[=LFE=Q&Q4``$7<*P"8
M"4OD*)\LBA#@)<8L/L>)`.G)``TX2J24GW+ZRM/L1_/<B4B*B<0$@:LLT-O4
ME*VDPX(T4$BR,)R0SD0<3C)4R_R)#PQ5)$7\*-ZDB2@:OYC8`$9ZSYJXI08@
MRI_I/YSDT/NQT)OX4/]14:*X-QX$1P`HI^+#P!%0"_FI$_F1-PT-S-9L"EC\
M3)GP3*+(N7**'R9=_L4#U8D$%=).M+\'=9\(!;OO?"V/<LJ96,Y%<ABR\TTQ
ME0DR521M$X$.B#6IN<5S[`OB$TQ&"E*E0%.=6%/_P4FB($C,&!@?C!^&&]*8
M4,69P$*CHI*9\(`*D(!S8TJ90,((N*28\("J](!D,X]L#$_%^9D6<\SP1).?
MX1810#\,&%$T$5#OPRLHD1J^6TVN`<(X6H'7?-,-<,HK78$(D!^WD=5`L0#5
M`M45`($HX1HJ^9D!(DHCW=+[Z%(A_$00\*@YO0E"G,P5\+EIA:1J=4>/PM97
M%+T94E6:J%-;I=:?](D29:1NK8EK98KV),E)Q4!IW!X?-=1L[5$*[43-_I2)
MK((2?56I<K+$.-(F^4K-#"@<O'+,!9BV<XU/6TV6ACW4=MP>^LM2=V75VC%4
M2[R<2K)&BLV`;#*2UZ1'<MU5'N3&QRQ!DC5/=*E2"3`KQ^DV-W/6^\C-?ZQ"
MG$A,1FI6G!!)!SA+1IH)GETDG[T)D8S+HN@<PU2DD<%919(`K?$U<LV)HE6D
MH[6)I&6*6P(_LBQ2FGB5$HB)KR12`/#%FG"<^3D`L_H;+#M054%;54F5Q%E5
MY_G*)CU;?X59O:58`2L<F,#7F8B?\%05!6#0C;7,*AU)$G'%U[2`L;T)E-78
MD502;L3;AW62*'V<5<51FUT.:)W++YT)DU0D_MAK6O\1VD4B78\ZW7S\B=+B
MTT4:&10`N\I$UITH7?]Q7;14"JG=0?G12[5@6YG@0;.=TA"HSMB\EX"-MYAP
MTMH5F1$H%Y6)GR"U32>UT[SE.4JLOIA0-9O(.0<8`?\3S">:P#44WH?%H'8]
MRYG@P7(*WK0\T/8$`(49@9%Y%=7D03_]W.((74ARM)X`RYZ04?LQV][-5^8L
M8(_"TY]H(`S`RQR4B0N8Q)TLP@7F"0.N'P<^"@Z@49NHI-1SMIFX)8NDV%S$
MO9CH`!94F.R=B>:QE_C!`$?Y54.US5[E.1P.V'R]1]NT5HUUQPK(IC4$/QY4
MVS3=U0F<3/GIR^*M_E*U50$[9![WY`"E9$G_G0\`]B@%F%"<V.).2RN.`^,.
M"TR<()$,0-T.*[[HY<14S5C=M!\S)@H1R$0N\<'M.<?SLY.]/.%\C4!PQ1Y]
M#<>:<-+X,>/X:5F(%=@G7N07ID3C-;X@3HP*$$;;1%0[+=$I5>"9R"8GP>3U
M]3X:SMMYR>*;U:S0^P#9720;^^(XECZ*[5TRYC!#5#4UUKGIVV",`[]9WBP'
MS0EZ],^?.0`#B5G4K!,0.+15*Z=D,=L1E<?!M=^'->.X-9`@WI)$7@$4=>2^
M71EN1ML_MMOV]3XFK:0GNN1V;&3FK=MKK-+HI8`BI@G,C1?Y&<8)K)/R_C7E
MY&#'Z2.!Y_2?#_/65Z:?OASC@0;#F@B!5:9#\+O:/*PFF>AES?KEOJ!(5F7-
MN7!!*[G$D;%8-K&D:WR`873#P\A&3YRKP\C>Q*R`4S42ZPUEE3J=+<%>'E9%
M470;YZ4)*&WG.")DOYW?^'Q9>2U7^I7$6OWI]ZU2N019"AE)+5%??3X.?@9%
MWYR?]I7HC\(K@SYH^54W"1[%FG!H.F1JK/8HJ`X*U!4P)]19>CS@P3JT:;J)
M:7H`"^"`1W68XW-/&#D8]YR,<#R`M.)!R6%9+BF<D\9`(PD!P\9F^9EB%"A!
MP';77I6?IJ2)<`PW^4&A^`DI"D'L2DM-J[PN_OEIT0-@Z6@&@"E^"\_N3?+S
M`"R4@#2-:M.8:A*E98'FZOC%OK*&)+2U)IVC`'--RZK6K+[<;48"YZ<@@1'H
MW]<8@30-%5P+W_YM$Y\P`04<"N6FXZ:!H-%0U?JJ6MD^#:C%'QU<:/_I8._#
M[5@>VO0^Z'+ZYT4J;=P*;LS@`.7-0Y(T;E8.;_[6/MH&10[KRM/F:K3=:O4>
MP[(L-PUM1IV`M0KX:E^V6_7N;PIGOO\.6]M.#(]:@-$C7]'S<!$`<1'O<!)O
M&HZKWQ0-<1+_\!57<19_\2!IXP#&8GQD\)YP$?V#\$62*BYV<1\?<1@'\JZI
M<"+_NPN?B7(<S$SS_LVG\#DF9PJQOA^=Q>#9'0J[C&#D`],$+G(N#\3QOA]#
MU.7[:4WSIA_F%@J?*_/Y.?.?\,VL'?`J/PHH\<T@57/Y8?,NS_/L._+LY#`"
M,6%&`E>E\#E`7R1!-PH2@TLJG>"GU`V1-))"5Z1#UW-*[SX^3^K-FE,4CV_.
MH[_HY@F?V_2U['31B^T5^'+)U(W[CG-&D57]XQGY\5R@7B3F`DM2__1*S_6?
MN_29T/'[L<HHMY\43EO[D9J@Y`!?*U^R"_;Z&7::4%OZD0"%^YEDKR^/VF0%
M_3Z5@J0YIHEM7MULAR1GGPEHGQ]I;TQD%STMU75V[Q14AT"=B'1NA<F/_NI7
MS"AW5B<[$_BH"_@/9H?`5$S3?X=WW<4?3\P)7P_:>>)W?]=VHX`24-V2J21`
MJ7C3P`XIJ.QVG>``"C#UL&B@8YT)8]4`#R"0I)$:#%`<-?P`"."KM#A56(4-
M385)"Y"`1:40JJ3H=I_MB<Y=/R?WCQK"`)GS#%QP]@9Z+B[Y2>U#CQJ71*]0
MNP`!7X=W,9\?VH1).Y\^?`=1I9\GIJ_0I`#T1E[D0YT*57QAGP#EJ!A=HUC7
M7$X]0:X`;>M#FRA:L[RE?K=$.T9RSIQ&,GEPK5C7;=QY_.#UF7AW^V'JX8UC
MJUR]XLS(IJEJ7-D:++?MQX<DOAJ]\Q/)H5Y\_MT$;Z#`0B/%0L2E$KWD>/.(
M8=#D;*+P3ZB@'U-E8X4E1[+GDO"$]LO9=S]6&B>.B1*4B63!D6F=Q37%<\+G
M>8?O3`ZS2ALU1BU4ON;G12\>>$Y<6-WL_>_532]&BJ\\QPG4XS='^ZV((IWW
M"0G`0&@FU;P%`+OH5AVEQ,T6S.G+`.7-?HB-GR0YZ^._P9Y700X#B`HK!@[D
M`.`@PH0*%S)DB($@P88,(4(T*/$BQH0/"8K(Z/'C00D$'X`LF?`!18(639;<
MF/(ES)0F$*(8&`*ABH$1.'+@(&*@!``[47#8P(%H!`XK4%B0\('GAI\H-'#H
MP-0I1!--*W"@:N)#_DB?`T50D)"AYL`/7C]`P(`V)E`4)`$TR"EBP]B0+TW`
M77&PPXJ9!RVLB'"`[T`0'"(<+-AX14<`/RU*X("X+^;,FC=S[NSY,^C0HD>3
MYASYH]+,%EC^A(B!)4B7$$'&?`W;H^R!&6XOM(T1Y4`4!WAG5)`3IF_B#7.7
M7A$40.H+<P&3T#`;.E``(E=8K+`;``8)%0Z2B(C=.8`%XLG;!&#<X(&CE,6"
M55KA<%X`#S(,%XA9)`G#`7`!9*E]EQIG*@!PP''?N:=`:RNH(-!SV0$PT`@'
M*37700<`UAR((8HX(HDEFEC::1XAV!<*+&U7D7(-K7B=1W"M%&-",PZD_H(#
M,2HE($;'!08DC@@]("1,-Q9YWH@>'*1`8!AT<!!*&91G7FJ,;6=1>4$9YQ>3
M&F;'()BI*7#>04^!B9>$P_$%@G;YX6519MO!>5!4J3W')F?UP=CA91745"%Z
M%T*F(0H22$`D""<Z^BBDD4HZ:7ZH;9;<1Q%R=&:1$,9$&UPB<(JCIS"IT`!O
MI8Z7T8<[/K=D!DC&).J2I98HH`@^J2!@HA2)B=Z6CP6UW:]E9D<LFLFF]NN4
MAD964V23/=;7BRMEH&>QFTD@&PGB<7I`31R$8"&YAS(9V&KZ4;HNN^VZ^VZ&
M(.D8TZXFO0B1"AP0"9L"K<($*ESY[LO2`OZ:_NI@21P(>5-&]P[4P:C$57"E
M9@(K5_"CWV&PTPJV-3#CKT%Q3&=A<1H[T*]:HGQ>4!DL=5!KOY(<K;D_;3`M
M7/>F"P";W_FWF08/O"4<E'(=Y/(!BBX:$@FVY>=!2LV^.S7555L=6HH9S1N3
MDAYI"A$*'TS`D@(6C(L9P"QZL&I)99^MF0F82O3Q6P2]>M'7-ED0,4C[U<T9
M"FN3;7:D+?YZVM\AFTSRL"LCJ#BRJ9GPP`$AO&:=XXX9&N]/D8W`'<XQW7OJ
MX0<M8-J18YE@4&HDZ-50KH_%2S%$BUY].^ZYZ[Z[3!UP4('2PRI];0A_MVN"
M[\`KK=WPXAK/60B__@>O*%?%GXA"KADH'?$#BEXK@JRB(2_]\L$3_[RC08%+
MT)D4I)3RXL(*E3G](M._0@A<:5`WG@,)EM<!\B,M0X'@`!`(GW,H(APF/2=O
MC9+)`:YEE`#>#$&H(HP(,B@"5$D&!8;+"Y160((35&0"O#LA"E.HPA6RL(4N
M=-24"*02`*CI.M@*EJ$:=[*3Z5!F`$#@031@@L\%A2^L$R#H<IBM'34@)1U!
MD`I(X@`D84!'452(2%H$G!4L``"7*=<*-`"`SQED7()!4`6^^,(ULK&-;GPC
M'.-8&OP0Q`0!I$AD!(6",RG`@ZL"P1[=@X)F"<I<>CP3N`@Y*(4T`&IA_J12
M31+UL0C.$`"QXN!/IA0?BI1@/!OX6U<HP@$%'*"*&9C`VVJW$#:%0`&5D8`"
M4CD0".`,`Q]3@)H2]:2BT$Z.OOPE,(,IS&&R2XTBI!K#%((6$GPN*R)`'TPD
M($L6O01[(X`F9IC92Q:!3X$B&`$"B2G.<9*SG.8\9]4R@`$-QBYOH4$!!-`I
MSWG2LY[VO"<Z-TF0$6R1-$0))SX#*M"!$K2@!B61""K0`.K%ZJ`.?2A$(RK1
MB5*THA:]*$8SJM&-<K2C'OTH2$,JTI&2M*0F/2E*4ZK2E;*TI2Y]*4QC*M.9
MTK2F-KTI3G.JTYWRM*<^_2E0@RK4H1*UJ$8%_IM:>G*9J2@U-"KPG0;<22*#
M53-O@^Q*3YX9/:R"`*!'_2I8BWI%]PAI5\UTZA)+U`$RP:4I,)E+#<4XH+#2
MM:Y?7<F]'`::M)*()#6LYD&>UT""R'5K=CTL8F_:$X2X#"BEX:N((A/")!U$
MAA09K.8,F]C-<K:E46D6`#YT+Q%D(`)8"<YB,/"!RX0``A,K%FDE``%9DL4L
M4RE!<#!@`:]:`%<QX>#Z+@NS2FJVL\8][DC%8IL#=(D@4T*!"L[T(0P81P0'
M:`WK5&";U(`%NF>JH9]6A5W(1LEG,.G`!SBHH^><U2+%12Y\XYM1L:P`N+T:
MR'"4TD/FKJ`#/U&0_A<#\ZOAX,5^+W/6<&O&M6?2Y"6"`HM[4H+9%=SL7/*]
M,(8O2M_H4NE%XQD72;;#*:7D1&KT^_`*0NR8[=`L.-C<SJH:FY7&"DB6$W9O
MAG.L8XE&A2`!0@A%V'*F[4!8.SDAV0[["TN3Z;#%F.E`!C)8X>`2Q`(?R."J
M''9C\NZXRUZ6)WW3`N2!D.`!1]*A"$><1"SYKP%G9K+).*>9RO1DE&G"UP/J
MO)*ZL9>X7_XSH,'\M>\$YTSCTN%34/`:D3`,,6+B<*,,O!O@M%C1NWU)KB`"
MX2:J1%.VD7&A(E3A]P:ZU*9FHP:F&10,:<@$0\8O"?UB)NQ`6"F1X0`)M[K(
MXH,8,<$XEO!9)820UNR*(@QC:ZC]?.IE,YN-83O``_ZZE!`NT$,6`8P"%)`!
MX!WGQQ+0I%OJ=0"UW+F_"Y)`NEKCY!VMA@)70D$(!`0A%*#J*/[#JPD&B9`*
M:)53T?9JLP,N<!1>1@7@Q!!:[+)-$?"E;BKH)F3JACV#)S@PV!PXQC-^TW5K
MO.,>SRG'/R[RD;N4*5PF.<I3KO*5L[SE+G\YS&,N\YG3O.8VOSG.<Z[SEP8$
#```[
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
